<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; key</title>
	<atom:link href="http://www.tapanray.in/tag/key/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Is Drug Price Control The Key Growth Barrier For Indian Pharma Industry?</title>
		<link>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/#comments</comments>
		<pubDate>Mon, 19 Oct 2015 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AIOCD-AWACS]]></category>
		<category><![CDATA[apex]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[corollary]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crocin Advance]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health care UHC]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[increases]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safeguard]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7183</guid>
		<description><![CDATA[The corollary of the above headline could well be: “Are drug price hikes the key growth driver for the Indian Pharmaceutical Market (IPM)?” Whenever the first question, as appears in the headline of this article: “Is drug price control a &#8230; <a href="http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Would &#8216;Empowered Patients&#8217; Hold The Key For Rapid Progress of Healthcare In India?</title>
		<link>http://www.tapanray.in/would-empowered-patients-hold-the-key-for-rapid-progress-of-healthcare-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=would-empowered-patients-hold-the-key-for-rapid-progress-of-healthcare-in-india</link>
		<comments>http://www.tapanray.in/would-empowered-patients-hold-the-key-for-rapid-progress-of-healthcare-in-india/#comments</comments>
		<pubDate>Sun, 27 Apr 2014 23:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Angelmar]]></category>
		<category><![CDATA[Becton]]></category>
		<category><![CDATA[CFF]]></category>
		<category><![CDATA[Dickinson]]></category>
		<category><![CDATA[Empowered]]></category>
		<category><![CDATA[empowerment]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[INSEAD]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PCORI]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5201</guid>
		<description><![CDATA[Empowered patients would eventually hold the key of rapid progress of healthcare all over world. It has to happen in India too and is just a matter of time. One such approach has recently been initiated in America. ‘The Patient-Centered Outcomes &#8230; <a href="http://www.tapanray.in/would-empowered-patients-hold-the-key-for-rapid-progress-of-healthcare-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/would-empowered-patients-hold-the-key-for-rapid-progress-of-healthcare-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Medical Tourism: A key growth driver in the healthcare space of India</title>
		<link>http://www.tapanray.in/medical-tourism-a-key-growth-driver-in-the-healthcare-space-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=medical-tourism-a-key-growth-driver-in-the-healthcare-space-of-india</link>
		<comments>http://www.tapanray.in/medical-tourism-a-key-growth-driver-in-the-healthcare-space-of-india/#comments</comments>
		<pubDate>Mon, 25 Jul 2011 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Space]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tourism]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=224</guid>
		<description><![CDATA[Since the last several years medical tourism is fast evolving as one of the key growth drivers of the healthcare sector, especially, in the western world like, the United States of America (USA) and the United Kingdom. Dr. Fred Hansen &#8230; <a href="http://www.tapanray.in/medical-tourism-a-key-growth-driver-in-the-healthcare-space-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/medical-tourism-a-key-growth-driver-in-the-healthcare-space-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Access to affordable healthcare to 65% of Indian population still remains a key issue even after six decades of independence of the country.</title>
		<link>http://www.tapanray.in/access-to-affordable-healthcare-to-65-of-indian-population-still-remains-a-key-issue-even-after-six-decades-of-independence-of-the-country/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=access-to-affordable-healthcare-to-65-of-indian-population-still-remains-a-key-issue-even-after-six-decades-of-independence-of-the-country</link>
		<comments>http://www.tapanray.in/access-to-affordable-healthcare-to-65-of-indian-population-still-remains-a-key-issue-even-after-six-decades-of-independence-of-the-country/#comments</comments>
		<pubDate>Mon, 12 Apr 2010 01:30:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[65%]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[after]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[decades]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Even]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[independence]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remains]]></category>
		<category><![CDATA[six]]></category>
		<category><![CDATA[still]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=442</guid>
		<description><![CDATA[Despite so much of stringent government control, debate and activism on the affordability of modern medicines in India, on the one hand, and the success of the government to make medicines available in the country at a price, which is &#8230; <a href="http://www.tapanray.in/access-to-affordable-healthcare-to-65-of-indian-population-still-remains-a-key-issue-even-after-six-decades-of-independence-of-the-country/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/access-to-affordable-healthcare-to-65-of-indian-population-still-remains-a-key-issue-even-after-six-decades-of-independence-of-the-country/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India as a global pharmaceutical outsourcing hub: Some key advantages and the areas of improvement.</title>
		<link>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement</link>
		<comments>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/#comments</comments>
		<pubDate>Mon, 04 Jan 2010 00:30:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[advantages]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[areas]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[Contract]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[hub]]></category>
		<category><![CDATA[improvement]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Some]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=488</guid>
		<description><![CDATA[All over the world, pharmaceutical research and development pipelines are gradually getting dried up. Lesser and lesser blockbuster drugs are now coming up from the ‘mind to the market’. Currently the average annual turnover of over 90% of patented drugs &#8230; <a href="http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Envisaging ‘five emerging key strategic changes’ in the Indian Pharmaceutical Industry</title>
		<link>http://www.tapanray.in/envisaging-five-emerging-key-strategic-changes-in-the-indian-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=envisaging-five-emerging-key-strategic-changes-in-the-indian-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/envisaging-five-emerging-key-strategic-changes-in-the-indian-pharmaceutical-industry/#comments</comments>
		<pubDate>Thu, 27 Aug 2009 00:30:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[five]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=797</guid>
		<description><![CDATA[In India, the domestic pharmaceutical market has clocked a CAGR of around 13% to 14% since the last five years. Currently, the market is dominated by the drugs for mass ailments. However, such trend has already started showing a shift &#8230; <a href="http://www.tapanray.in/envisaging-five-emerging-key-strategic-changes-in-the-indian-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/envisaging-five-emerging-key-strategic-changes-in-the-indian-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Drug Policy 2009 – suggesting key elements for a strategic shift in the policy framework</title>
		<link>http://www.tapanray.in/new-drug-policy-2009-suggesting-key-elements-for-a-strategic-shift-in-the-policy-framework/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-drug-policy-2009-suggesting-key-elements-for-a-strategic-shift-in-the-policy-framework</link>
		<comments>http://www.tapanray.in/new-drug-policy-2009-suggesting-key-elements-for-a-strategic-shift-in-the-policy-framework/#comments</comments>
		<pubDate>Mon, 01 Jun 2009 00:30:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2009]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[elements]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[suggesting]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=872</guid>
		<description><![CDATA[The new drug policy of the Government of India (GoI) is long overdue. Despite so many reform measures taken by various Governments over last two decades, Indian Pharmaceutical Industry has not seen a new &#8216;drug policy&#8217;since 1995.As an individual who &#8230; <a href="http://www.tapanray.in/new-drug-policy-2009-suggesting-key-elements-for-a-strategic-shift-in-the-policy-framework/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-drug-policy-2009-suggesting-key-elements-for-a-strategic-shift-in-the-policy-framework/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Key business strategies of global pharmaceutical industry are undergoing a radical change, while in India we are still thinking within the box. Who cares about the global clue?</title>
		<link>http://www.tapanray.in/key-business-strategies-of-global-pharmaceutical-industry-are-undergoing-a-radical-change-while-in-india-we-are-still-thinking-within-the-box-who-cares-about-the-global-clue/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=key-business-strategies-of-global-pharmaceutical-industry-are-undergoing-a-radical-change-while-in-india-we-are-still-thinking-within-the-box-who-cares-about-the-global-clue</link>
		<comments>http://www.tapanray.in/key-business-strategies-of-global-pharmaceutical-industry-are-undergoing-a-radical-change-while-in-india-we-are-still-thinking-within-the-box-who-cares-about-the-global-clue/#comments</comments>
		<pubDate>Thu, 14 May 2009 04:23:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[about]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[box]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cares]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[clue]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Key business strategies of global pharmaceutical industry are undergoing a radical change]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[radical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[still]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[thinking]]></category>
		<category><![CDATA[undergoing]]></category>
		<category><![CDATA[we]]></category>
		<category><![CDATA[while]]></category>
		<category><![CDATA[while in India we are still thinking within the box. Who cares about the global clue]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[within]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=887</guid>
		<description><![CDATA[One of the leading consulting companies, PricewaterhouseCoopers (PwC) in its report of June 2007 titled “Pharma 2020: The vision –Which path will you take?” postulated that the business model followed by the global pharmaceutical companies is, “economically unsustainable and operationally &#8230; <a href="http://www.tapanray.in/key-business-strategies-of-global-pharmaceutical-industry-are-undergoing-a-radical-change-while-in-india-we-are-still-thinking-within-the-box-who-cares-about-the-global-clue/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/key-business-strategies-of-global-pharmaceutical-industry-are-undergoing-a-radical-change-while-in-india-we-are-still-thinking-within-the-box-who-cares-about-the-global-clue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
